Cargando…

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay

AIM: The 21-gene recurrence score (RS) predicts a clinical benefit of chemotherapy for individuals with ER-positive/HER2-negative breast cancer. Using in vitro chemoresponse assay, we compared the chemosensitivity according to RS in these patients. METHOD: Among the patients with Oncotype Dx assay,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Sung Gwe, Bae, Soong June, Yoon, Changik, Cha, Yoon Jin, Lee, Hak Woo, Lee, Seung Ah, Jeong, Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695596/ https://www.ncbi.nlm.nih.gov/pubmed/29117208 http://dx.doi.org/10.1371/journal.pone.0187679

Ejemplares similares

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
por: Park, Inho, et al.
Publicado: (2023)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program
por: Park, Jung Min, et al.
Publicado: (2017)

Comparison of complications according to incision types in nipple-sparing mastectomy and immediate reconstruction
por: Park, Soeun, et al.
Publicado: (2020)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
por: Bae, Soong June, et al.
Publicado: (2020)

Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer
por: Lee, Yangkyu, et al.
Publicado: (2022)

Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
por: Ji, Jung Hwan, et al.
Publicado: (2022)

A nomogram constructed using intraoperative ex vivo shear-wave elastography precisely predicts metastasis of sentinel lymph nodes in breast cancer
por: Bae, Soong June, et al.
Publicado: (2019)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
por: Baek, Seung Ho, et al.
Publicado: (2022)

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer
por: Yoon, Chang Ik, et al.
Publicado: (2019)

Evaluation of chemoresponse assays as predictive markers
por: Korn, E L, et al.
Publicado: (2015)

Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2019)

Relationship of the standard uptake value of (18)F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
por: Park, Soeun, et al.
Publicado: (2021)

Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2023)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Overview of a chemoresponse assay in ovarian cancer
por: Grendys, E. C., et al.
Publicado: (2014)

Comment on: ‘Evaluation of chemoresponse assays as predictive markers'
por: Tian, C, et al.
Publicado: (2015)

Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
por: Cha, Yoon Jin, et al.
Publicado: (2022)

Response to Comment on: ‘Evaluation of chemoresponse assays as predictive biomarkers'
por: Korn, E L, et al.
Publicado: (2015)

Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence After Breast Conserving Surgery With Sentinel Lymph Node Biopsy: Pooled Analysis Using Data From a Systematic Review and Two Institutions
por: Yoon, Chang Ik, et al.
Publicado: (2020)

High Nuclear Expression of Yes-Associated Protein 1 Correlates With Metastasis in Patients With Breast Cancer
por: Cha, Yoon Jin, et al.
Publicado: (2021)

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Expression of Heat Shock Protein 70 Modulates the Chemoresponsiveness of Pancreatic Cancer
por: Hyun, Jong Jin, et al.
Publicado: (2013)

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor–Positive, ERBB2–Negative Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2022)

Ex Vivo Shear-Wave Elastography of Axillary Lymph Nodes to Predict Nodal Metastasis in Patients with Primary Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2018)

Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Metastasis Risk Assessment Using BAG2 Expression by Cancer-Associated Fibroblast and Tumor Cells in Patients with Breast Cancer
por: Yoon, Chang-Ik, et al.
Publicado: (2021)

(18)F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence
por: Kim, Hyun Jeong, et al.
Publicado: (2022)

Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
por: Choi, Hyungwook, et al.
Publicado: (2023)

The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients
por: Cha, Yoon Jin, et al.
Publicado: (2021)

The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer
por: Matondo, Abel, et al.
Publicado: (2017)

Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score
por: Ahn, Sung Gwe, et al.
Publicado: (2013)

Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer
por: Yoon, Chang Ik, et al.
Publicado: (2020)

In vitro chemoresponse in metachronous pairs of gyneclologic cancers
por: Dalton, Heather J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3egsihm93chq7354ghla3ss8u4